Alzheimer's Disease

APOE4 carriers had higher blood-brain barrier permeability, even without cognitive decline or amyloid beta buildup, suggesting early vascular changes that may be linked to Alzheimer’s risk and neurodegeneration.

A study found untreated hypertension increases Alzheimer's risk by 36% and non-Alzheimer's dementia risk by 69%. Treating hypertension lowers these risks, highlighting the importance of antihypertensive medication.

Researchers discovered that Alzheimer’s disease progresses in two phases: a slow, early phase with silent damage to specific brain cells, followed by a faster, symptomatic phase. These insights could lead to earlier detection and targeted treatments.

Researchers have discovered that non-neuronal brain cells, oligodendrocytes, produce about 30% of amyloid plaques in Alzheimer’s disease. This challenges the neuron-focused understanding of plaque formation and could lead to new therapeutic strategies targeting oligodendrocytes to slow disease progression.

Lower caffeine consumption was linked to a higher risk of memory impairment and worse Alzheimer's disease biomarkers, suggesting caffeine might offer protective effects against cognitive decline. However, more research is needed to confirm any direct benefits.

New research suggests that exposure to artificial light at night may increase the risk of Alzheimer’s disease, particularly in younger people, highlighting light pollution as a potential factor in the rise of neurodegenerative conditions.

Researchers discovered that some brain cells age faster than others, especially in people with Alzheimer’s disease. Women’s brains also show more of these rapidly aging cells, which may increase their risk for neurodegenerative disorders.

UCLA researchers have discovered a compound, DDL-920, that restores memory and cognitive function in Alzheimer’s model mice by enhancing brain gamma oscillations, offering a potential new treatment that goes beyond slowing disease progression.

Alzheimer’s disease risk is more strongly influenced by maternal genetics, with higher amyloid plaque levels in those with a maternal history of memory loss, suggesting mitochondrial dysfunction may play a key role.

Scientists have uncovered a significant clue to understanding why some individuals are more susceptible to Alzheimer’s disease.

A new study has found that genetic predispositions for neuroticism may predict the onset of Alzheimer's in individuals with amnestic mild cognitive impairment.

Higher cognitive reserve improves cognitive functioning in older adults, but stress, indicated by cortisol levels, reduces this benefit. The study highlights the interplay between cognitive reserve, stress, and Alzheimer's biomarkers.

Scientists found that genes related to immune activity may help some people resist Alzheimer’s symptoms, even with high amyloid levels, highlighting lifestyle and genetic factors in disease resilience.

Researchers developed an AI model that predicts Alzheimer's progression with 78.5% accuracy by analyzing speech patterns from neuropsychological tests, offering a non-invasive early detection method.

Type 2 diabetes patients treated with GLP-1 agonists, like Ozempic, have a reduced risk of developing dementia compared to those on older diabetes medications, according to a new study.